Summary: An enzymatic spectrophotometric method for determination of myo-inositol in serum is described. The method is sensitive and rapid to perform without special equipment. Linearity between the amount of /wyo-inositol and absorbance was obtained in the ränge of 0.5 to 3 nmol wyo-inositol per assay. The amounts of wyo-inositol determined in sera from apparently healthy subjects agree well with gas Chromatographie data.
Introduction
mjw-Inositol, a cyclic isomer of D-glucose, occurs in plants, animals and human beings in its free form and bound in phospholipids and phytic acid. There is evidence that alterations in Anyö-inositol metabolism may play a role iii a number of diseases such äs diabetes mellitus, renal and hepatic dysfunctions and atherosclerosis (l, 2) . Despite this fact, data on myo* inositol content and metabolism are relatively scarce due to a lack of methods that combine high sensitivity and easy performance. Up tö riow myo-inositol levels have been measured by microbiologicaj (3, 4) , spectrophotometric (5, 6) , fluorimetric (7) and gas^chro* matographic (8, 9) methods. The present wofk describes a sensitive enzymatic assay for myo-inositol, which does not üeed special equipment and is easy to perform. The results have been preseiited in part elsewhere (10) .
Materials and Methods
Chemicals wyö-Inositol, bathophenanthroline disulphönie acid, phenazine methosulphate, myo-inositol dehydrogenase 2 ) and 3-(N-morpholino) propanesidphonic acid were from Sigma (Taufkirchen, FRG). Glucose oxidase and catalase were from Boehringer (Mannheim, FRG). All other chemicals were from Merck (Dannstadt, FRG).
Subjects
Serum was obtained from 69 apparently healthy subjects, from 25 persons with impaired kidney function (creatinine > 106 / ) and from 56 patients with normal kidney function (creatinine < 106 / ), including 18 diabetics, 15 and 7 patients suffering from malignant diseases and diseases of heart and circulation, respectively, and 16 patients with various other diseases.
Sample preparation To 0.3 ml serum 0.005 ml 300 mmol/1 NaN 3 and 0.02 ml glucose oxidase reagent (100 mmol/1 3-(N-morpholino)propanesulphonic acid buffer, pH 7.0, containing 700 kU/1 glucose oxidase 2 ) and 3500 kU/1 catalase 2 )) were added. After incubation in stoppered micro-vessels at 37 °C overnight, samples were deproteinized with 0.3 ml l mol/1 HC1O 4 prior to centrifugation. The supernatant was neutralized with soh'd KHCO 3 . KC1O 4 was remqved by centrifugation and the clear supernatant was analysed for m>?ö-inositol content.
Assay of wj>0-inositol
To 0.05 ml of the sample were added 0.1 ml distilled water and 0.05 ml of a 2 -bathophenanthroline disulphonic acid (13) , which is measured spectrophotoiiietrically by an increase in absorbance at 546 nm ( fig. 1) . Under the coiiditions of the assay described, oxidation of myo-inositol does not proceed to completion, but NADH formation is proportional to myoin sitol concentration (5, 6). my0-Inositol was therefore determined in a fixed-time kinetic assay. Thus a calibration curve for determination of myoinositol content of samples was required.
Due to the high molar lineic absorbance of the ferrous bathophenanthroline disulphonic acid complex (2150 m 2 /mol (14)), the sensitivity of the assay allowed m^o-inositol measurements s low s 0.5 nmol/assay (corresponding to about 6 μπιόΐ/ΐ) which is one order of magnitude lower than that described by Weissbach (5, 6) . Figure 2 shows that the incfease in absorbance was linear up to 3 nmol/assay. For human serum there was a linear relationship between the amount of serum employed and the amount of myo-inositol recovered ( fig. 3) . myolnositol, added to human serurn, was recovered in high yield (tab. 2). As to reproducibility, intra-assay coefficients of Variation for the whole serum procedure (including glucose oxidase treatment, deproteinization and neutralization) were 7.5% (mean value = 45 μηιοΐ/l, n = 7) and 7.3% (mean value = 70 μίηοΐ/ΐ, n = 9), respectively, while the between-run coefficient of Variation was 9.5% (mean value = 40 μηιοΐ/ΐ, η = 9).
As to specificity, serious interference was observed by glucose. Thus glucose conceiitrations of 5.5 and 27.7 mmol/1 yielded values corresponding to 90 and 340 μιηοΐ/ΐ myo-inpsitol, respectively. Hence it is necessary to remove glucose by treatment of the samples with glucose oxidase prior to mj; -inositol measurement. mj;0-Inositol in serum is stable against this treatment (data not shown). Ethanol (20 mmol/1) is slightly registered in the assay, seemingly corresponding to 7 μπιοΐ/ΐ myo-inositol.
No interference was found by the following substanĉ es (tested at 0.1 namol/1): acetaldehyde, acetoacetate, N-acetylglucosamine, dihydroxyacetone, fructose, galactose, galactitol, glucosamine, glyceraldehyde, glycerol, -^hydroxybutyrate, mannose, mannitol, ribose, ribitol, sorbitol, xylose and xylitol. From these results it is reasonable to coiiclude that the assay is . not subject to seriotis interference by substances pre·Ĵ / (mean value = 31 /1). These values agree well with gas-chromatographic data (15 -18) . wyö-Inositol levels are normally distributed and not dependent on sex or age.
In confirmation of reports from other laboratories (9, 15 -17) , myo-mositol was found to be markedly elevated in serum from patients. with renal failure. Furthermore, in these patients a clear correlation was observed between wy0-inositol and creatinine levels (n = 25, r = 0.769). A small but statistically significant increase in myo-inositol was also found in diabetics and patients suffering from malignant diseases.
Since the method described herein is sensitive and rapid to perform without special equipment, it may be useful not only for myo-inositol determination in serum, but also for the investigation of myo^inositol content and metabolism in biological fluids other than serum, or in tissues.
